Why the study?
Randomized data comparing the impact of PCI with CABG or contemporary guideline-directed medical therapy alone on clinical outcomes and myocardial recovery in patients with heart failure are lacking.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Observational studies suggest a benefit with percutaneous coronary intervention (PCI) in patients with heart failure (HF), but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking.”
“The use of percutaneous coronary intervention (PCI) in HF patients with CAD has markedly increased and has been suggested to be associated with improved outcomes in numerous observational studies. Randomized data comparing the impact of PCI with that of coronary artery bypass graft (CABG) or contemporary guideline-directed medical therapy alone on clinical outcomes and myocardial recovery in patients with HF are lacking.”
“Due to the upfront risk of mortality with CABG, it is logical to consider that percutaneous coronary intervention could potentially amplify the benefit of revascularization noted in STICH.”
Does not support routine PCI adoption in HF; leaves open its comparative role versus CABG or medical therapy pending RCTs.
Coronary artery disease (CAD) is highly prevalent in patients with heart failure (HF) and accounts for nearly two-thirds of cases. The use of percutaneous coronary intervention (PCI) in HF patients with CAD has markedly increased and has been suggested to be associated with improved outcomes in numerous observational studies. Randomized data comparing the impact of PCI with that of coronary artery bypass graft (CABG) or contemporary guideline-directed medical therapy alone on clinical outcomes and myocardial recovery in patients with HF are lacking. The purpose of this review is to describe the available evidence regarding the impact of PCI in acute HF (in the presence and absence of an acute coronary syndrome), chronic HF with reduced ejection fraction, and HF with preserved ejection fraction. Adequately-powered randomized clinical trials examining the outcomes with PCI in these distinct HF populations are warranted.
No takes yet. Share an insight, caveat, or question.
Parikh et al. (2021) conducted a review in Heart failure with coronary artery disease. Percutaneous coronary intervention (PCI) vs. Coronary artery bypass graft (CABG) or guideline-directed medical therapy was evaluated. This review highlights the lack of adequately-powered randomized clinical trials comparing percutaneous coronary intervention to CABG or medical therapy in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: